Home / Business and Economy / FDA Eases Biosimilar Drug Testing Rules
FDA Eases Biosimilar Drug Testing Rules
9 Mar
Summary
- FDA plans to ease testing requirements for biosimilar drug developers.
- New guidance could cut $20 million from biosimilar development costs.
- Policy aims to lower medicine prices by making drug approval easier.
The U.S. Food and Drug Administration is preparing to relax testing mandates for companies creating biosimilar drugs. As of March 9, 2026, draft guidance is anticipated as early as Monday, March 10, 2026, aiming to reduce the necessity for specific studies that confirm biosimilar medications are equivalent to their brand-name counterparts.
This policy adjustment could decrease biosimilar development expenses by approximately $20 million. The FDA views this as a crucial step towards making it simpler for businesses to secure drug approvals in the United States. The broader goal is to lower prescription medicine costs by promoting biosimilar alternatives.
Biosimilars are complex medicines derived from living cells, unlike standard pills that can be exactly replicated. The Department of Health and Human Services, which oversees the FDA, has not yet commented on the impending changes.
